Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort
James J Anderson, Edmund M Lau, Melanie Lavender, Raymond Benza, David S Celermajer, Nicholas Collins, Carolyn Corrigan, Nathan Dwyer, John Feenstra, Mark Horrigan, Dominic Keating, Fiona Kermeen, Eugene Kotlyar, Tanya McWilliams, Bronwen Rhodes, Peter Steele, Vivek Thakkar, Trevor Williams, Helen Whitford, Kenneth Whyte Show all
Chest | ELSEVIER | Published : 2020
BACKGROUND: Pulmonary arterial hypertension (PAH) prognosis has improved with targeted therapies; however, the long-term outlook remains poor. Objective multiparametric risk assessment is recommended to identify patients at risk of early morbidity and mortality, and for optimization of treatment. The US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 risk score is a new model proposed for the follow-up of patients with PAH but has not been externally validated. METHODS: The REVEAL 2.0 risk score was applied to a mixed prevalent and incident cohort of patients with PAH (n = 1,011) from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) Regist..View full abstract
Funding support for the Pulmonary Hypertension Society of Australia and New Zealand Registry was provided by Actelion Pharmaceuticals, Allied Healthcare, Bayer, GlaxoSmithKline, Novartis, and Pfizer. GlaxoSmithKline provided research funding support for the primary author.